PL3204034T3 - Preparaty farmaceutyczne pegylowanych liposomów i czynników krzepliwości krwi - Google Patents

Preparaty farmaceutyczne pegylowanych liposomów i czynników krzepliwości krwi

Info

Publication number
PL3204034T3
PL3204034T3 PL15775444.1T PL15775444T PL3204034T3 PL 3204034 T3 PL3204034 T3 PL 3204034T3 PL 15775444 T PL15775444 T PL 15775444T PL 3204034 T3 PL3204034 T3 PL 3204034T3
Authority
PL
Poland
Prior art keywords
pharmaceutical formulations
blood coagulation
coagulation factors
pegylated liposomes
pegylated
Prior art date
Application number
PL15775444.1T
Other languages
English (en)
Polish (pl)
Inventor
William Henry
Original Assignee
Cantab Biopharmaceuticals Patents Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantab Biopharmaceuticals Patents Limited filed Critical Cantab Biopharmaceuticals Patents Limited
Publication of PL3204034T3 publication Critical patent/PL3204034T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL15775444.1T 2014-10-06 2015-10-06 Preparaty farmaceutyczne pegylowanych liposomów i czynników krzepliwości krwi PL3204034T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1417589.7A GB201417589D0 (en) 2014-10-06 2014-10-06 Pharmaceutical Formulations
PCT/EP2015/073003 WO2016055447A1 (en) 2014-10-06 2015-10-06 Pharmaceutical formulations of pegylated liposomes and blood coagulation factors

Publications (1)

Publication Number Publication Date
PL3204034T3 true PL3204034T3 (pl) 2023-11-06

Family

ID=51946871

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15775444.1T PL3204034T3 (pl) 2014-10-06 2015-10-06 Preparaty farmaceutyczne pegylowanych liposomów i czynników krzepliwości krwi

Country Status (16)

Country Link
US (2) US20170304203A1 (enExample)
EP (1) EP3204034B9 (enExample)
JP (3) JP2017531659A (enExample)
AU (1) AU2015330102B2 (enExample)
BR (1) BR112017007031A2 (enExample)
CA (1) CA2994891C (enExample)
ES (1) ES2954134T3 (enExample)
GB (1) GB201417589D0 (enExample)
HR (1) HRP20230985T1 (enExample)
HU (1) HUE063656T2 (enExample)
MX (1) MX384517B (enExample)
PL (1) PL3204034T3 (enExample)
RS (1) RS64461B1 (enExample)
RU (1) RU2737291C2 (enExample)
SM (1) SMT202300271T1 (enExample)
WO (1) WO2016055447A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201417589D0 (en) * 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
JP6825010B2 (ja) * 2016-05-26 2021-02-03 ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ 遠心法によるリポソーム調製のための方法及び装置

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6326353B1 (en) 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
DE69418334T2 (de) 1993-08-06 2000-01-27 Opperbas Holding B.V., Amsterdam Verfahren zur hohen beladung von vesikeln mit biopolymeren substanzen
IL113010A (en) * 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US6156337A (en) * 1994-07-08 2000-12-05 Opperbas Holding B.V. Method for high loading of vesicles with biopolymeric substances
US6310183B1 (en) * 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
MXPA00010241A (es) * 1998-04-27 2004-09-06 Opperbas Holding Bv Composicion farmaceutica que comprende el factor viii y liposomas neutrales..
RU2250911C2 (ru) * 1999-07-14 2005-04-27 Элзэ Копэрейшн Липосомальная композиция, нейтральный липополимер и способ увеличения времени циркуляции липосомы
AU2001256148A1 (en) * 2000-05-03 2001-11-12 Novo-Nordisk A/S Subcutaneous administration of coagulation factor vii
US20030232075A1 (en) 2002-05-06 2003-12-18 University Of Minnesota, A Minnesota Corporation Compositions for producing factor Xa
DE602004013769D1 (de) 2003-04-15 2008-06-26 Opperbas Holding Bv Pharmazeutische zusammensetzung, enthaltend proteine und/oder polypeptide sowie kolloidpartikel
JP2008544990A (ja) * 2005-06-29 2008-12-11 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 低免疫原性蛋白質−脂質複合体に関する組成物および方法
EP2099475B1 (en) * 2007-01-03 2016-08-24 Novo Nordisk Health Care AG Subcutaneous administration of coagulation factor viia-related polypeptides
CA2701884A1 (en) 2007-10-15 2009-04-23 Wake Forest University Health Sciences Methods and compositions for printing biologically compatible nanotube composites of autologous tissue
AU2010255391C1 (en) 2009-06-03 2016-10-27 Sequessome Technology Holdings Limited Formulations for the treatment of deep tissue pain
MX336482B (es) 2009-08-21 2016-01-21 Henk-Andre Kroon Formulaciones vesiculares.
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
TW201240664A (en) * 2010-09-01 2012-10-16 Portola Pharm Inc Methods and formulations of treating thrombosis with betrixaban and a P-glycoprotein inhibitor
EP2838566A2 (en) * 2012-04-16 2015-02-25 Cantab Biopharmaceuticals Patents Limited Optimised subcutaneous therapeutic agents
GB201417589D0 (en) * 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations

Also Published As

Publication number Publication date
HUE063656T2 (hu) 2024-01-28
JP7573582B2 (ja) 2024-10-25
JP2023002687A (ja) 2023-01-10
AU2015330102A1 (en) 2017-05-25
RS64461B1 (sr) 2023-09-29
EP3204034A1 (en) 2017-08-16
CA2994891A1 (en) 2016-04-14
CA2994891C (en) 2023-04-04
US20170304203A1 (en) 2017-10-26
JP2017531659A (ja) 2017-10-26
HRP20230985T1 (hr) 2023-12-08
WO2016055447A1 (en) 2016-04-14
EP3204034B9 (en) 2023-10-04
EP3204034C0 (en) 2023-06-07
US11484499B2 (en) 2022-11-01
RU2017115831A3 (enExample) 2019-05-06
RU2017115831A (ru) 2018-11-14
US20190060235A1 (en) 2019-02-28
MX384517B (es) 2025-03-14
EP3204034B1 (en) 2023-06-07
SMT202300271T1 (it) 2023-09-06
ES2954134T3 (es) 2023-11-20
GB201417589D0 (en) 2014-11-19
MX2017004378A (es) 2018-02-09
JP2020183446A (ja) 2020-11-12
BR112017007031A2 (pt) 2018-01-30
AU2015330102B2 (en) 2021-01-28
RU2737291C2 (ru) 2020-11-26

Similar Documents

Publication Publication Date Title
IL285179A (en) Pharmaceutical preparations containing synthetic glycans for use in the treatment of diseases of the digestive system and methods and methods for their preparation
IL279001A (en) Nasal medicines and methods of using them
IL265590B (en) Formulations and methods for keratin treatment
IL251834B1 (en) Pharmaceutical compositions containing peptide variants and methods of using them
ZA201703163B (en) Rna guided eradication of human jc virus and other polyomaviruses
ZA201807128B (en) Pegylated liposomes and methods of use
EP3202305A4 (en) Disposable endoscope and system
EP3131566A4 (en) Bi-terminal pegylated integrin-binding peptides and methods of use thereof
GB201500314D0 (en) Pharmaceutical formulations for the treatment of pulmonary arterial hypertension
IL256515A (en) Therapeutic peptides and methods of use thereof
PT3380525T (pt) Formulações farmacêuticas e métodos que as utilizam
IL248210A0 (en) Methods and compositions for the treatment of vascular malformation
EP3313427A4 (en) Therapeutic peptides and methods of use thereof
ZA201802134B (en) Therapeutic compounds and methods of use thereof
GB201406172D0 (en) Therapy and pharmaceutical composition
EP3154637A4 (en) Treatment of virus-based diseases of the skin
PL3204034T3 (pl) Preparaty farmaceutyczne pegylowanych liposomów i czynników krzepliwości krwi
HUE061056T2 (hu) Készítmény meddõség kezelésére nõi betegnél
GB201410869D0 (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
IL257689A (en) Pharmacological preparations and methods for the treatment of diseases associated with hypoxia
KR20180085033A (ko) 피부 질환 치료용 약학적 제형 및 이의 제조 방법
GB201408449D0 (en) Motion-activated therapeutic disposable pillowcase
GB201414414D0 (en) Formulations of generic drugs against cancer and infectious diseases